One in four people living with HIV in the United States are women. So why is HIV prevention medication overwhelmingly only targeted at men who have sex with men?
San Francisco Supervisors David Weiner and Scott Campos last week held a hearing to discuss the efforts of a coalition formed to end HIV in a city that was once seen as a center of the epidemic in this country.
Because Depo-Provera is an important contraceptive choice and because in many parts of the world, it is the only long-acting, discreet option available to women, it is vital to take the issue of a link between HIV and hormonal contraception quite seriously while adding nuance to the discussion.
For women in countries and communities with limited contraceptive choices and high rates of HIV, particularly in sub-Saharan Africa, a shortage of funding for the ECHO (Evidence for Contraceptive Options and HIV Outcomes) trial is an unacceptable development.
Doctors were devastated to announce last week that their patient, an almost 4-year-old girl was once thought “cured” of HIV, was found to have detectable viral loads and lowered T-cell counts.
This week, a novel approach to infertility is announced, a new vaginal ring might be able to protect from HIV transmission, and the answer to preventing drug-resistant gonorrhea may be in our own immune systems.
Do we do more harm than good when we bandy about the word “cure” in a case like this?
There’s been much talk this week about the “miracle cure” of a child with HIV. But what about the unjust health-care system that failed her mother?
When it comes to making sure taxpayer-funded AIDS programs are comprehensive and designed to deliver the most effective interventions for people in need, the Obama administration’s track record has not been good.
For too many, accessing health care is a challenge. Integrating reproductive health and HIV/AIDS services–providing both services under one roof–makes it easier for women to get what they need.